Strategic agreements for Takeda’s portfolio in Oncology and Gastroenterology
Takeda Pharmaceutical Company Limited announced the acquisition of ARIAD Pharmaceuticals, Inc. on January 9th 2017, an oncology-focused biotechnology company with a portfolio of targeted therapies that is highly complementary to Takeda’s existing oncology business. Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of approximately $5.2 billion.
The acquisition of ARIAD brings two innovative targeted therapies that will transform Takeda’s existing oncology portfolio and pipeline by expanding into solid tumors and reinforcing the existing strength in hematology. Takeda’s current portfolio of hematology products is...